Last Update 10 Jul 26
Fair value Decreased 4.15%PATH: AI Automation And ARR Execution Will Drive Future Repricing
UiPath's analyst fair value estimate has been trimmed from $17.00 to about $16.29 as analysts adjust their price targets into a tighter $12 to $15 range. This reflects solid recent results, but also a preference to see stronger, more consistent ARR momentum and clearer AI driven benefits before becoming more positive.
Analyst Commentary
Recent research on UiPath points to a mixed but constructive tone, with most price targets now clustering in the low to mid teens and analysts looking closely at execution on Annual Recurring Revenue (ARR) and the real impact of AI related demand on growth and valuation.
Bullish analysts highlight that UiPath delivered what several described as solid or good fiscal Q1 results, with revenue coming in above their expectations and guidance for revenue and margins moving higher. These analysts see evidence that the company is executing against its current plan, even if ARR momentum and larger AI related deals are still viewed as areas where the company needs to show more progress over multiple quarters.
At the same time, there is an ongoing debate around how quickly AI driven automation demand can translate into stronger net new ARR and whether UiPath can show a more consistent pattern across its customer cohorts and pricing. Some analysts are holding neutral or equivalent ratings while they look for clearer signals that recent performance can be sustained and that newer pricing approaches, such as non seed based models, are gaining traction.
Valuation views are tied closely to this execution debate. Several firms have nudged price targets lower into a tighter range, reflecting a preference to see more evidence of durable ARR growth before assigning higher multiples. A few, however, point to UiPath trading at a discount to certain software peers and suggest that consistent progress on AI driven deals, enterprise adoption, and ARR trends could help close that gap over time if delivered.
Bullish Takeaways
- Bullish analysts point to UiPath’s fiscal Q1 revenue coming in above their estimates, along with raised full year guidance, as evidence that the company is currently executing in line with or slightly ahead of expectations on the top line.
- Some see larger AI driven deals and strength within enterprise cohorts as potential supports for net new ARR growth. If sustained, this could help justify valuations closer to the upper end of the current price target range.
- One major bank increased its UiPath price target, citing good quarterly results and an outlook that it viewed as supportive relative to the company’s current discount to certain infrastructure software peers.
- Bullish analysts indicate that additional data points showing a more consistent ARR growth trajectory, particularly tied to AI use cases, could support a more constructive stance on the stock over time.
What’s in the News for UiPath
- UiPath reported its first ever GAAP operating profit of US$28 million in fiscal Q1 FY2027, with AI playing a role in 16 of the top 20 deals and AI inclusive expansions generating roughly 6x more revenue. Management also highlighted perceived undervaluation through meaningful share repurchases. (Source: UiPath Price Forecast: PATH Posts First-Ever GAAP Profit as AI Deals Grow 6x Larger)
- New AI native Maestro Case capability was introduced within the Maestro orchestration platform to handle complex, exception heavy, long running workflows. Early adopters, such as a major New Zealand telecom, reported case handling time reductions of 60 to 80%, higher automation levels, and projected annual savings of more than US$12 million in financial services use cases. (Source: UiPath Launches AI-Native Maestro Case to Enhance Complex Enterprise Workflow Automation Amid Mixed Market Response)
- UiPath’s Q1 results across automation software peers were mixed, with revenue ahead of expectations but full year billings guidance described as weak relative to the group. This coincided with a stock price decline and contributed to more cautious commentary around forward recurring revenue expectations. (Source: A Look Back at Automation Software Stocks’ Q1 Earnings: UiPath (NYSE:PATH) Vs The Rest Of The Pack)
- Guidance for fiscal Q2 2027 and the full year was provided, with the company expecting revenue of US$395 million to US$400 million for the quarter and US$1.776b to US$1.781b for the year, giving investors concrete top line ranges to watch against future reported results.
- Alongside these financial updates, UiPath continued to roll out AI focused capabilities such as UiPath for Coding Agents and agentic AI features in Automation Suite, positioning its platform around orchestration of AI agents, software robots, and people across regulated and hybrid environments.
Valuation Changes for UiPath
- Fair Value: The analyst fair value estimate for UiPath moved from $17.00 to $16.29, a reduction of about 4.2% that keeps the figure within the previously discussed $12 to $15 target range.
- Discount Rate: The discount rate moved from 8.51% to 8.61%, a small increase that modestly raises the required return used in the valuation model.
- Revenue Growth: The revenue growth input shifted from 9.40% to 8.77%, a slight step down that implies a more conservative growth assumption in the model.
- Profit Margin: The profit margin assumption changed from 9.69% to 24.02%, a large uplift that reflects a materially higher long term profitability input.
- Future P/E: The future P/E multiple moved from 52.31x to 19.43x, a significant reduction that lowers the valuation placed on UiPath's projected earnings.
Catalysts
About UiPath
UiPath provides an end to end automation and AI platform that helps enterprises automate complex workflows across systems, people and software.
What are the underlying business or industry changes driving this perspective?
- The shift toward AI driven operating models is encouraging large customers to adopt UiPath’s agentic and AI products on top of existing unattended automation. This can widen platform usage and support ARR growth and higher net retention over time.
- Enterprises are increasing cloud deployment of automation, and UiPath reported over US$1.2b in cloud ARR. This positions the company to capture more recurring revenue as customers standardize automation and orchestration in the cloud.
- Growing complexity of cross system workflows is pushing companies to look for a unified control layer. UiPath’s Maestro and coding agents are designed to shorten automation build times, which can support faster revenue realization and potentially improve operating margins through efficiency gains.
- Rising compliance and governance requirements in sectors such as financial services and the public sector are steering buyers toward platforms with strong auditability and security. UiPath’s focus on governance can help support premium pricing and resilient net margins.
- Health care and financial services are seeing increased interest in revenue cycle, financial crime and other high stakes use cases where UiPath is building dedicated solutions and integrating WorkFusion. This can support higher expansion rates, larger deal sizes and earnings growth as these offerings scale.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on UiPath compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming UiPath's revenue will grow by 8.8% annually over the next 3 years.
- The bullish analysts assume that profit margins will increase from 19.6% today to 24.0% in 3 years time.
- The bullish analysts expect earnings to reach $516.8 million (and earnings per share of $0.99) by about July 2029, up from $327.4 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $268.5 million.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 19.4x on those 2029 earnings, up from 18.7x today. This future PE is lower than the current PE for the US Software industry at 29.3x.
- The bullish analysts expect the number of shares outstanding to decline by 2.43% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.61%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- AI and automation demand may increasingly favor usage based or pure SaaS models. UiPath still accounts for a meaningful mix of hybrid and non SaaS ARR, which could slow new ARR if large customers prefer alternatives and weigh on revenue growth.
- Growing competition in agentic AI and orchestration from system of record vendors and AI native providers, some of which customers already use for core workflows, could limit adoption of Maestro and UiPath agents and put pressure on pricing, which would affect ARR expansion and net margins.
- If AI products and vertical solutions such as healthcare revenue cycle or financial crime agents fail to scale as expected or take longer to integrate with WorkFusion than planned, the mix shift toward higher value AI ARR may stall and reduce the contribution to earnings growth and operating margin expansion.
- The company is leaning heavily on partners and large, complex projects in regulated sectors like public sector, financial services and healthcare. Any slowdown in these long sales cycle markets or delays in long term projects could dampen large deal volume and weigh on revenue and earnings.
- Management is targeting higher long term non GAAP operating margins and expects continued GAAP profitability. However, heavier cloud investment, stock based compensation, internal use of agents and potential tuck in acquisitions could keep costs elevated and limit further improvement in net margins and free cash flow.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for UiPath is $16.29, which represents up to two standard deviations above the consensus price target of $13.25. This valuation is based on what can be assumed as the expectations of UiPath's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $17.0, and the most bearish reporting a price target of just $10.98.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $2.2 billion, earnings will come to $516.8 million, and it would be trading on a PE ratio of 19.4x, assuming you use a discount rate of 8.6%.
- Given the current share price of $11.8, the analyst price target of $16.29 is 27.6% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on UiPath?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
